8-K: Coherus Oncology Unveils Strong LOQTORZI Growth, 2025 Cash

Coherus Oncology, Inc. reported preliminary unaudited net revenues for Q4 and full year 2025, along with cash position, and projected significant growth for its LOQTORZI product.

Summary

• Preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, and cash, cash equivalents, and investments as of December 31, 2025, will be presented at the 43rd Annual J.P. Morgan Healthcare Conference.
• Cash, cash equivalents, and investments stood at $172.1 million at the end of Q4 2025, which is expected to support operations through the end of 2026.
• LOQTORZI annual revenues are projected to reach $150-200 million by 2028 within a $250 million market.
• LOQTORZI quarterly revenues for 2025 are projected as: Q1 $7.3 million, Q2 $10.0 million, Q3 $11.2 million, and Q4 ~$12.3 million.
• LOQTORZI demand growth is projected at 10-15% quarter-over-quarter.
• The clinical stage pipeline includes Tagmokitug (anti-CCR8 cytolytic antibody) with readouts for HNSCC, GC, GEJ, EAC expected in mid-2026, and CRC, ESCC in H2 2026, with additional indications starting in 2026.
• Casdozokitug (IL-27 antagonist) has a readout for HCC expected in mid-2026.
• Future plans include exploring Tagmokitug novel combinations, Ex-US licensing, and LOQTORZI US supply agreements.

Sentiment

Score: 7

Explanation: The filing presents positive preliminary financial projections for LOQTORZI and a robust clinical pipeline with multiple upcoming readouts, supported by a strong cash position. However, the financial results are unaudited and preliminary, and the company highlights risks related to market acceptance and future funding.

Positives

• Strong preliminary cash position of $172.1 million at the end of Q4 2025, expected to fund operations through the end of 2026.
• LOQTORZI is projected to achieve significant revenue growth, reaching $150-200 million by 2028.
• Consistent projected quarter-over-quarter growth for LOQTORZI demand (10-15%).
• Robust clinical pipeline with multiple readouts expected for Tagmokitug and Casdozokitug in 2026 across various cancer indications.

Negatives

• The financial results presented are preliminary and unaudited, subject to change, and have not been reviewed or audited by an independent registered public accounting firm.

Risks

• The Company's ability to raise funds, which may not be available on acceptable terms or at all.
• Risks and uncertainties regarding the degree of market acceptance for the Company's product by physicians, healthcare providers, and patients.
• Risks and uncertainties of litigation.
• Actual results, performance, or achievements could differ significantly from forward-looking statements due to substantial risks and uncertainties.

Future Outlook

Coherus Oncology projects strong demand and revenue growth for LOQTORZI, expecting it to reach $150-200 million in annual revenues by 2028. The company also anticipates multiple clinical trial readouts for its pipeline assets, Tagmokitug and Casdozokitug, throughout 2026, targeting various cancer indications. Strategic initiatives include exploring novel combinations for Tagmokitug, Ex-US licensing, and US supply agreements for LOQTORZI.

Industry Context

The oncology market is highly competitive, with significant demand for innovative cancer treatments. LOQTORZI's projected growth within a $250 million market segment indicates a focused strategy on a specific niche. The development of novel antibodies like Tagmokitug (anti-CCR8) and antagonists like Casdozokitug (IL-27) reflects the industry's ongoing shift towards targeted therapies and immunotherapies, which are key areas of innovation and investment in oncology.

Comparison to Industry Standards

• LOQTORZI's projected annual revenue of $150-200 million by 2028 within a $250 million market suggests a significant market share capture, indicating strong competitive positioning for a relatively new product.
• The projected 10-15% quarter-over-quarter growth for LOQTORZI is a healthy growth rate for a commercial-stage oncology product, comparable to successful launches in the targeted therapy space.
• The pipeline with Tagmokitug and Casdozokitug, targeting indications like HNSCC, GC, HCC, and CRC, aligns with major unmet needs in oncology, similar to other biotech companies developing next-generation immunotherapies.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through LOQTORZI revenue growth and pipeline advancements, but also exposure to risks related to preliminary financial data, market acceptance, and future funding.
• Patients: Potential for new treatment options with Tagmokitug and Casdozokitug in various cancer indications.
• Healthcare Providers: Continued availability and growing demand for LOQTORZI.

Next Steps

• Present preliminary unaudited financial results at the 43rd Annual J.P. Morgan Healthcare Conference.
• Complete financial closing procedures for Q4 and fiscal year ended December 31, 2025.
• Continue clinical development of Tagmokitug with readouts for HNSCC, GC, GEJ, EAC (mid-2026), CRC, ESCC (H2 2026), and additional indications starting in 2026.
• Continue clinical development of Casdozokitug with readout for HCC (mid-2026).
• Explore Tagmokitug novel combinations.
• Pursue Ex-US licensing opportunities.
• Secure LOQTORZI US supply agreements.

Key Dates

Recommendation

The preliminary financial results for LOQTORZI show promising growth and the company's cash position is strong enough to support operations through 2026. The robust clinical pipeline with multiple upcoming readouts in 2026 also presents future upside. However, the results are unaudited and preliminary, and the company explicitly highlights risks related to market acceptance and the ability to raise future funds. Given the mix of positive projections and inherent risks, a 'hold' recommendation is appropriate, awaiting audited results and further clarity on pipeline progress and market penetration.

Keywords

Coherus Oncology, CHRS, LOQTORZI, Tagmokitug, Casdozokitug, Oncology, Biotechnology, Cancer Treatment, SEC Filing, Financial Results, Pipeline, Clinical Trials, Head and Neck Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma